Immunity after COVID-19 vaccination: a scoping review

The objective of the planned scoping review is to provide an overview on the existing literature on immune response and long-term efficacy outcomes after COVID-19 vaccination, and to map this evidence according to the examined populations, specific vaccines, immunity parameters and their way of determining relevant long-term outcomes and the availability of mapping between immune reactivity and relevant outcomes. We will limit inclusion to literature on the four vaccines currently authorized by the EMA and vaccines authorized in at least 10 countries worldwide: • Comirnaty [Pfizer / Biontech], • Spikevax [Moderna], and its equivalent TAK-919 [Moderna formulation, Takeda] • Vaxzevria [Oxford / AstraZeneca] and its equivalent Covishield [Oxford / AstraZeneca formulation, Serum Institute of India] • COVID-19 Vaccine Janssen [Ad26.COV2.S] • Sputnik V [Gamaleya] • Sputnik Light [Gamaleya] • BBIBP-CorV (Vero Cells) [Sinopharm (Beijing)] • CoronaVac [Sinovac] (COVID-19 Vaccine (Vero Cell) Inactivated)